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Background: Neuroinflammation and protein accumulation are characteristic hallmarks of both normal aging and
age-related neurodegenerative diseases. However, the relationship between these factors in neurodegenerative
processes is poorly understood. We have previously shown that proteasome inhibition produced higher
neurodegeneration in aged than in young rats, suggesting that other additional age-related events could be
involved in neurodegeneration. We evaluated the role of lipopolysaccharide (LPS)-induced neuroinflammation as a
potential synergic risk factor for hippocampal neurodegeneration induced by proteasome inhibition.
Methods: Young male Wistar rats were injected with 1 μL of saline or LPS (5 mg/mL) into the hippocampus to
evaluate the effect of LPS-induced neuroinflammation on protein homeostasis. The synergic effect of LPS and
proteasome inhibition was analyzed in young rats that first received 1 μL of LPS and 24 h later 1 μL (5 mg/mL) of
the proteasome inhibitor lactacystin. Animals were sacrificed at different times post-injection and hippocampi
isolated and processed for gene expression analysis by real-time polymerase chain reaction; protein expression
analysis by western blots; proteasome activity by fluorescence spectroscopy; immunofluorescence analysis by
confocal microscopy; and degeneration assay by Fluoro-Jade B staining.
Results: LPS injection produced the accumulation of ubiquitinated proteins in hippocampal neurons, increased
expression of the E2 ubiquitin-conjugating enzyme UB2L6, decreased proteasome activity and increased
immunoproteasome content. However, LPS injection was not sufficient to produce neurodegeneration. The
combination of neuroinflammation and proteasome inhibition leads to higher neuronal accumulation of
ubiquitinated proteins, predominant expression of pro-apoptotic markers and increased neurodegeneration, when
compared with LPS or lactacystin (LT) injection alone.
Conclusions: Our results identify neuroinflammation as a risk factor that increases susceptibility to
neurodegeneration induced by proteasome inhibition. These results highlight the modulation of
neuroinflammation as a mechanism for neuronal protection that could be relevant in situations where both factors
are present, such as aging and neurodegenerative diseases.* Correspondence: ruano@us.es
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Neuroinflammation has distinct features that are shared
in aging and in neurodegenerative diseases. Microglia
are the main immune cell in the brain, playing a role in
both physiological and pathological conditions [1-5]. Al-
though acute neuroinflammation plays a protective role
[6-8], chronic neuroinflammation is frequently con-
sidered detrimental and damaging to nervous tissue
[2,3]. Thus, whether neuroinflammation has benefi-
cial or harmful outcomes in the brain may critically
depend on both the duration of the inflammatory re-
sponse and the kind of microglial activation [9]. As
the primary source for proinflammatory cytokines, micro-
glia are implicated as a pivotal mediator of neuroinflam-
mation and can induce or modulate a broad spectrum of
cellular responses [10].
In relation to protein homeostasis, some proinflam-
matory cytokines, such as IFN-γ and TNF-α, can alter
the proteolytic activity of the proteasome, leading to
the switch to immunoproteasome (i-proteasome) [11,12].
The proteasome is a molecular complex that controls
intracellular protein homeostasis by degrading mis-
folded and/or regulatory proteins. It is made up of
the 20 S-proteasome, a central unit carrying the catalytic
activities, and several regulatory complexes such as
PA700/19 S or PA28/11 S [13]. The 26 S-proteasome
(19 S-20 S-19 S) is responsible for the catalysis of the
ATP-dependent degradation of polyubiquitinated proteins
formed by a cascade of E1, E2 and E3 enzymes, which
activate, conjugate and transfer, respectively, multiple
ubiquitin molecules to protein substrates, thus target-
ing these for degradation [13-15].
As mentioned before, following IFN-γ or TNF-α
stimulation, or after LPS injection, the constitutive cata-
lytic subunits β1, β2 and β5 are replaced by the indu-
cible catalytic subunits β1i, β2i and β5i, in order to form
the i-proteasome that associates with the regulatory
complex PA28/11 S [12,16,17]. Because substrates of
proteasomes are short-lived regulatory proteins involved
in cell differentiation, cell-cycle regulation, transcrip-
tional regulation or apoptosis [18], a rapid and efficient
elimination of proteins by the ubiquitin proteasome sys-
tem (UPS) is essential under stress conditions that cause
the accumulation of misfolded or partially denatured
proteins [19].
Despite neuroinflammation and proteasome dysfunc-
tion being two significant hallmarks in many neurode-
generative diseases, the relationship between the factors
is poorly explored. Here, we have evaluated the potentialrole of neuroinflammation on the UPS. Our results
provide strong evidence supporting a synergic effect of
neuroinflammation and proteasome dysfunction for hip-
pocampal neurodegeneration.Material and methods
Animals
Young (3 to 4 months) and aged (24 to 26 months) male
Wistar rats were provided by the animal care facility of the
University of Seville. All experiments were approved by
local ethical committees and complied with international
animal welfare guidelines.Surgery
Young male Wistar rats (200 to 250 g; n = 58) were pro-
cessed for surgery as previously described [20,21]. Differ-
ent groups of animals were established, rats injected
with LPS, rats injected with saline + LPS or saline + LT
or LPS + LT, and control rats injected with saline only.
For the rats injected with LPS, the LPS (Sigma-
Aldrich, St Louis, MO, USA) was dissolved (5 mg/mL)
in a solution of sterilized PBS and 1 μL was injected
into both hippocampi. The rats were anesthetized
with 400 mg/kg chloral hydrate and positioned in a
stereotaxic apparatus (Kopf Instruments, Tujunga, CA,
USA). According to Paxinos’ atlas, the coordinates were:
3.3 mm posterior, 1.6 mm lateral and 3.2 mm ventral to
the bregma and 4.8 mm posterior, 5.5 mm lateral and
6.0 mm ventral to the bregma. The injections were deliv-
ered over a period of 2 min and the needle was left in situ
for an additional 5 min to avoid reflux along the injection
track. Animals were decapitated at 3 hours, 6 hours, 14
hours, 24 hours, 3 days and 7 days after LPS injection and
brains were quickly removed. Control animals were pro-
cessed similarly but received 1 μL of sterilized PBS in both
hippocampi.
The procedure for rats injected with saline +LPS or sa-
line+LT or LPS+LT, the LT (Sigma-Aldrich) was dis-
solved (5 mg/mL) in a solution of sterilized PBS and 1 μL
was injected into both hippocampi. For each case, saline
or LPS was first administered and 24 hours later, LPS or
LT was injected through the same drilled hole. Finally,
animals were sacrificed 48 hours after the last injection. In
addition, male Wistar aged rats (24-month-old, n = 3)
were included in the saline +LT-injected group. Animals
were processed similarly but the coordinates were 6.0 mm
posterior, ± 4.6 mm lateral and 4.6 mm ventral to the
bregma as previously shown [22].
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Both hippocampi were dissected, frozen in liquid N2 and
stored at −80°C until use. Hippocampi were homoge-
nized in 700 μL of ice cold sucrose buffer (0.25 M
sucrose, 1 mM ethylenediaminetetraacetic acid, 10 mM
Tris–HCl, pH 7.4) supplemented with a protease inhibi-
tor cocktail (Sigma-Aldrich). Three hundred microliters
were separated and used for RNA isolation (see below).
The remaining homogenized solution (400 μL) was cen-
trifuged at 15,000 × g for 30 min at 4°C and the super-
natant was recovered and stored at −80°C until use.
Protein concentration was determined by the Lowry
method.RNA extraction, reverse transcription and real-time PCR
Total RNA extraction and reverse transcription was
carried out with 300 μL of each homogenized hippo-
campi sample as previously described [22]. Real-time
PCR was performed in an ABI Prism 7000 sequence
detector (Applied Biosystems, Madrid, Spain) using
cDNA diluted in sterile water as a template. Analyzed
genes were amplified using specific Taqman probes
supplied by Applied Biosystems. Threshold cycle (Ct)
values were calculated using the software supplied by
Applied Biosystems.
Proteasome activity assay
Proteasome activity was determined in hippocampal sam-
ples using specific fluorogenic substrates for the chymo-
trypsin activity of the proteasome. Proteasome activity was
abolished in the presence of 10 μM MG-132 [22].
Antibodies and immunoblots
The following primary antibodies were used in this study.
Rabbit polyclonal anti-inducible nitric oxide synthase
(iNOS; BD Bioscience, San José, CA, USA), anti-ubiquitin
(Dako, Glostrup, Denmark); anti-β5i subunit (Abcam,
Cambridge, UK), anti-proteasome maturation protein
(POMP; Biomol, Madrid, Spain), anti-Bax, anti-Bak, anti-
B-cell lymphoma extra large (Bcl-XL) and anti-Bcl-2 (Cell
Signaling, Danvers, MA, USA), and anti-caspase-3
(Stressgen, Ann Arbor, MI, USA); mouse monoclonal
anti-β-actin (Sigma-Aldrich) and anti-neuronal nuclei
(NeuN; Chemicon, Billerica, MD, USA); horseradish-
peroxidase-conjugated corresponding secondary anti-
bodies (Dako); and secondary antibodies conjugated
to DyLight fluorophores (Jackson Inmunoresearch,
Madrid, Spain). Immunoblots were performed as
previously described [20,22].
Immunofluorescence and confocal microscopy
Animals were transcardially perfused with 4% parafor-
maldehyde and brains were processed as previouslydescribed [2]. Sections 25 μm-thick were cut on a
cryostat and mounted on gelatin-coated slides, per-
meabilized with 0.5% Triton (Sigma-Aldrich) over-
night at room temperature, incubated with primary
antibody anti-ubiquitin for 1 h at room temperature
and overnight at 4°C and, finally, with the appropriate
DyLightTM-conjugated-secondary antibodies for 1 h.
Nuclei were counterstained with 4′-6-diamidino-2-
phenylindole (DAPI) at a final concentration of 1 ng/μL
after secondary antibody labeling. Control staining
included omission of primary antibodies or irrelevant
primary antibodies of the same isotype. Then, sections
were washed and coverslipped with 0.01 M PBS con-
taining 50% glycerin and 2.5% triethylenediamine
and examined under a motorized upright wide-field
microscope (Leica DM6000B). Confocal images were
captured using a TCS SP5 Confocal Leica laser scan-
ning microscope equipped with a DMI60000 micro-
scope and an HCX PL APO lambda blue 63× 1.4 oil
objective at 22°C. Maximum projection image was
obtained.
Statistical analysis
Statistical analysis was performed using the Statgraphics
plus (v 3.1) software. The differences between groups in
the time-course experiments were assessed by one-way
analysis of variance followed by Turkey’s test. The
data comparison between the saline and saline + LT,
saline+LPS and LPS+LT animals was carried out using
two-tailed t-test. The significance was set at P <0.05. Sig-
nificant differences are indicated by an asterisk.
Results
LPS injection increases the content of ubiquitinated
proteins in hippocampal neurons
To analyze the role of LPS-induced neuroinflammation
on the UPS, we induced neuroinflammation in young rat
hippocampi by intrahippocampal injection of LPS. As
expected [21], LPS injection induced a significant in-
crease (P <0.05) early on in the mRNA expression of
proinflammatory factors such cytokines TNF-α and IL-1β,
and the enzyme iNOS (Figure 1), indicating the induction
of neuroinflammation. Interestingly, LPS injection also
increased the content of ubiquitinated proteins, mostly
those with high molecular weight (Figure 2A). The con-
tent of these ubiquitinated proteins was significantly
higher than in saline-injected rats from 14 hours to even
7 days after LPS injection (P <0.05; Figure 2B). Immuno-
fluorescence experiments revealed that ubiquitinated pro-
teins accumulated preferentially in the stratum pyramidale
of the CA3 (Figure 2C) and CA1 regions (data not
shown), where the cell bodies of principal neurons localize
as revealed by NeuN immunostaining (Figure 2C lower
panel).
Figure 1 Temporal changes in the expression of TNF-α, IL1-β
and iNOS mRNAs in the rat hippocampus after LPS injection.
The expression of mRNA coding for the proinflammatory cytokines
TNF-α and IL1-β and for the enzyme iNOS was quantified at
different times post-injection (from 3 hours to 7 days) in samples
from hippocampi injected with 5 μg of LPS. Data are presented as
the mean± SD relative to saline-injected animals. Data were
obtained from triplicate assays. In the insert is shown a
representative western blot for the iNOS enzyme in samples from
the same animals used for gene expression. *P <0.05. iNOS:
inducible nitric oxide synthase; IL1- β: interleukin-1 beta; LPS:
lipopolysaccharide; SD: standard deviation; TNF-α: tumor necrosis
factor alpha.
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ubiquitin-conjugating enzyme UB2L6, decreases
proteasome activity and increases immunoproteasome
biogenesis
We next investigated for potential factors that could ex-
plain the LPS-induced accumulation of ubiquitinated
proteins. In this sense, and based on data by others [23],
we considered the possibility that ubiquitin conjugation
activity increases after LPS injection. So, we analyzed the
mRNA expression of the E2 ubiquitin-conjugating en-
zyme UB2L6 at different times post-LPS injection. As
shown in Figure 3A, the mRNA expression of the E2
UB2L6 enzyme was transcriptionally up-regulated in a
time-dependent manner after LPS injection, being sig-
nificantly increased from 6 hours to 7 days after LPS in-
jection (P <0.05). In addition, LPS injection produced
an early and concomitant transcriptional up-regulation
of the rate-limiting i-proteasome subunit β5i, followed
by protein synthesis and i-proteasome biogenesis, as
reflected by the increase in both the mature form of the
β5i subunit [21] and POMP [24,25] (Figure 3B, C). The
β5i subunit was diffusely expressed in the strata oriens
and radiatum of the LPS-injected rats (72 hours after
LPS injection), suggesting a preferential expression in
neuronal projections rather than in neuronal bodies.
Some cellular bodies scattered in the stratum lucidum
of the hippocampus were also observed. These couldcorrespond to interneurons or glial cells. Importantly,
some degree of co-distribution between ubiquitin and
β5i subunit was observed in some pyramidal cells and
other cells in the stratum lucidum (Figure 3D). The
LPS injection also resulted in a transient decrease of
proteasomal chymotrypsin activity 14 to 24 hours
after injection, which was restored 7 days later (Figure 3E),
probably as consequence of the shift from constitutive
to i-proteasome. Taken together, these data indicated
that LPS injection transitorily alters protein homeo-
stasis in hippocampal neurons. Importantly, this
homeostatic alteration seemed to be not deleterious for
neurons because no evident signs of neurodegenera-
tion were observed (see below).
LPS-induced neuroinflammation increases
neurodegeneration produced by proteasome inhibition
Because LPS injection increased the content of ubi-
quitinated proteins in neurons and decreased proteasome
activity, we wondered whether neuroinflammation could
increase susceptibility to cellular death induced by prote-
asome inhibition. For that, we produced proteasome
inhibition 24 h after LPS injection, exactly when ubiquiti-
nated proteins accumulated and proteasome activity was
decreased (see above).
First, we analyzed at cellular level the distribution of
ubiquitinated proteins induced by saline+LPS, saline +LT
or LPS+LT injection at 72 hours (see Material and meth-
ods). As shown in Figure 4A (upper panel), ubiquitinated
proteins were mostly localized in pyramidal somata of the
CA3 region regardless of the treatment. A similar distribu-
tion was observed for the CA1 region (data not shown).
Importantly, in the LPS+LT group, the intensity of ubi-
quitin immunostaining was increased. Indeed, higher
magnification images from pyramidal cells revealed that
accumulation of ubiquitinated proteins in the CA3 neu-
rons of the LPS+LT animals concentrated mostly in peri-
nuclear regions as bigger structures. By contrast, in both
saline+LPS- or saline + LT-treated animals, ubiquitinated
proteins appeared distributed throughout the cytoplasm
as small punctuated structures (Figure 4A, lower panel).
To further test this potential synergism between neuroin-
flammation and protein accumulation in a more physio-
logical situation, we blocked the proteasome in aged rat
hippocampus where neuroinflammation was widespread
[2,4], and analyzed at cellular level the distribution of ubi-
quitinated proteins similarly as done in young rats. As
show in Figure 4B, accumulation of ubiquitinated proteins
was also observed in the CA3 region (and also in the CA1,
data not shown) and, importantly, higher magnification
images of pyramidal cells revealed accumulation of ubi-
quitinated proteins in perinuclear regions as bigger struc-
tures, similarly as observed in young LPS+LT-treated
rats. Thus, these data strongly indicate that age-related
Figure 2 Accumulation of ubiquitinated proteins induced by LPS injection. (A) Ubiquitinated proteins, predominantly those of high
molecular weight, accumulated in young rat hippocampi after LPS injection. Shown is a representative western blot experiment corresponding to
saline- and LPS-injected animals sacrificed at indicated times. Each line corresponds to four animals pooled and the experiment was repeated at
least three times with similar results. (B) Densitometric quantification of western blot experiments (n = 3). The full line, without the inclusion of
the free ubiquitin, was considered for the analysis. (C) Cellular distribution of ubiquitinated proteins in the CA3 region of saline (upper) and
3 days after LPS injection (middle). Most of the immunostaining was observed in the stratum pyramidale, where the somata of principal neurons
are located as revealed by the intense immunostaining of the neuronal marker NeuN (lower). Nuclei were counterstained with DAPI. *P <0.05
significant difference with respect to saline-injected animals. DAPI: 4′-6-diamidino-2-phenylindole; LPS: lipopolysaccharide; NeuN: neuronal nuclei;
sp: stratum pyramidale. Scale bar: 75 μm.
Pintado et al. Journal of Neuroinflammation 2012, 9:87 Page 5 of 10
http://www.jneuroinflammation.com/content/9/1/87chronic neuroinflammation is a synergic risk factor for
protein accumulation.
To investigate whether differences in the manner of
accumulation of ubiquitinated proteins could be related
to neurodegeneration, we analyzed the expression of
pro-survival and pro-apoptotic proteins in a new group
of animals that were sacrificed 24 hours after the last in-
jection. As shown in Figure 5A, the expression of the
pro-survival proteins Bcl-2 and Bcl-XL tended to in-
crease in all the experimental conditions analyzed, being
significantly higher in saline + LPS and LPS + LT rats
(P <0.05; see Figure 5C). However, the expression of the
pro-apoptotic proteins Bax and Bak (Figure 5B), was
strongly and significantly increased exclusively in the
LPS+LT animals (P <0.05; Figure 5C). On average, the
pro-apoptotic to pro-survival ratio was six-fold higher in
this group of animals compared to animals injected with sa-
line+LPS or saline+LT, indicating that LPS-induced neu-
roinflammation increases the susceptibility to cellular death
after proteasome inhibition. In fact, Fluoro-Jade B staining
revealed that the saline+LPS injection produced minimal
neurodegeneration, just in some neurons surrounding thetrack of injection, whereas the saline+LT injection induced
a moderate neurodegeneration, mostly in the pyramidal
cells of the CA3 region (Figure 6A; see also [22]). However,
and in agreement with biochemical data, the LPS+LT in-
jection strongly increased the number of Fluoro-Jade-
B-positive cells throughout the hippocampus. Import-
antly, most of the degenerative signal was observed in
the dentate gyrus, whereas in the CA3 region the number
of Fluoro-Jade-B-positive cells was scarce, probably be-
cause of the higher susceptibility of this hippocampal re-
gion to proteasome inhibition, as we have previously
shown to occur in aged rats [22]. Indeed, cresyl violet
staining revealed a patent decrease in the number of
pyramidal cells in both the CA1 and CA3 regions of
the LPS + LT rats (Figure 6A, panel c), and most
clearly, the expression of the neuronal marker NeuN
was practically absent in the LPS + LT-injected rats,
compared to both the saline + LPS and the saline + LT
animals (Figure 6A, panels d-f ). Finally, the neurode-
generative effect produced by the combination of
neuroinflammation and proteasome inhibition could
be mediated, at least in part, by apoptosis, as revealed
Figure 3 Modification of the UPS induced by intrahippocampal LPS injection. (A) Profile of the mRNA expression of the E2
ubiquitin-conjugating enzyme UB2L6 at different times post-LPS injection. Data are presented as the mean± SD relative to saline-injected animals.
Data were obtained from triplicate assays. (B) Profile of the mRNA expression of the β5i subunit (black line) in the same animals as in A. (C) At
the top is shown a representative western blot of the β5i subunit (mature form) in samples from rats injected with saline and LPS, sacrificed at
times indicated. Densitometric quantification of western blot experiments (n = 3) is shown in B (red line). At the bottom is shown a representative
western blot of POMP in the same animals as shown before. The experiment was repeated three times with similar results. Note the strong
time-dependent increase in the content of this protein involved in proteasome assembly, indicating an active process of de novo proteasome
biogenesis. (D) Immunofluorescence analysis of the cellular distribution of ubiquitinated proteins and the β5i in hippocampal slices from
LPS-injected rats. Images correspond to animals sacrificed 3 days after LPS injection. The β5i immunostaining was mainly located in neuronal
fibers in the stratum oriens and stratum radiatum. Some scattered cellular bodies were also observed in the stratum lucidum. Arrows indicate
colocalization of ubiquitin and β5i immunostaining. Bar scale 75 μm. (E) Chymotrypsin-like activity was analyzed in saline- and LPS-injected rats at
different times post-injection (n = 4 per time point). LPS injection significantly decreased the chymotrypsin activity of hippocampal proteasomes.
*P <0.05. LPS: lipopolysaccharide; POMP: proteasome maturation protein; sl: stratum lucidum; so: stratum oriens; sp: stratum pyramidale; sr:
stratum radiatum.
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(Figure 6B).
Discussion
In the present work we have evaluated the potential role
of neuroinflammation as a synergic risk factor for hippo-
campal neurodegeneration induced by proteasome inhib-
ition. Our results demonstrated that LPS injection, in
addition to the classical neuroinflammatory response
characterized by the production of proinflammatory
mediators, also altered protein homeostasis. In fact,LPS injection produced neuronal accumulation of
ubiquitinated proteins; de novo i-proteasome biogen-
esis; a transient decrease of the proteasome activity; and a
robust and sustained transcriptional up-regulation of the
E2 ubiquitin-conjugating enzyme UB2L6. Thus, the LPS-
induced accumulation of ubiquitinated proteins in
hippocampal neurons could be consequence of both
increased ubiquitin conjugation activity, to meet the
substrate demands of a strongly up-regulated antigen
presentation machinery, and the shift from constitutive to
i-proteasome upon neuroinflammation, to increase the
Figure 4 Proteasome inhibition after intrahippocampal injection of LPS induced the formation of aggresome-like structures in
hippocampal neurons. (A) Upper: immunofluorescence analysis of the cellular distribution of ubiquitinated proteins in hippocampal slices from
rats treated with saline, saline + LPS, saline + LT and LPS + LT. Images correspond to animals sacrificed 48 hours after the last injection. Lower:
higher magnification corresponding to neurons from the stratum pyramidale taken from images showed above. Nuclei were counterstained with
DAPI. Note the presence of large aggresome-like structures (arrowheads) only in the LPS + LT-injected rats. Bar scale: 75 μm for upper images and
10 μm for lower images. (B) Similar as in A but images correspond to aged rat hippocampus injected with LT alone.
DAPI: 4′-6-diamidino-2-phenylindole; LPS: lipopolysaccharide; LT: lactacystin; sp: stratum pyramidale.
Figure 5 Anti- and pro-apoptotic proteins expressed following
saline, saline+ LPS, saline + LT and LPS+ LT injection in rat
hippocampus. (A) Representative western blots showing the
expression of the anti-apoptotic proteins Bcl2 and Bcl-XL at 24 hours
after saline + LPS, saline + LT or LPS + LT injection. (B) Similar as in A
but for the pro-apoptotic proteins Bax and Bak. Experiment were
done in parallel and repeated four times with similar results.
(C) Densitometric analysis of western blots. Results were normalized
with β-actin and referred to saline-injected animals. Data are
presented as mean± SD compared to a pool of saline-injected
young animals. *P <0.05. Bcl: B-cell lymphoma; LPS:
lipopolysaccharide; LT: lactacystin; SD: standard deviation.
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Taken together, these data indicate that LPS-induced
modification of protein homeostasis could be part of
a more general neuroinflammatory response to in-
crease the production of peptides for antigen presen-
tation [17,30]. In support of this, viability of neurons
was well-preserved during the adaptation to this short
phase of reduced proteolytic activity, as judge by the ab-
sence of Fluoro-Jade B staining and the predominant ex-
pression of pro-survival proteins (see also [2]). However,
under this scenario (neuroinflammatory response), neu-
rons become more vulnerable to proteasome inhibition.
Indeed, proteasome inhibition after neuroinflammation
(LPS+LT) leads to an early and predominant expression
of pro-apoptotic proteins, followed by a qualitative in-
crease in the number of degenerating neurons. Moreover,
this combined treatment produced the formation of
aggresome-like structures exclusively in the LPS+LT-
treated rats. Similar structures have been previously
observed in vitro after treatment with IFN-γ in cells lack-
ing i-proteasome, suggesting that i-proteasome plays a
pivotal role in both cytokine-mediated inflammation and
the clearance of damage proteins and aggresome-like
structures [24]. In this sense, our in vivo results are sup-
porting this view. LPS injection produced a sustained ex-
pression of i-proteasome and the accumulation of
ubiquitinated proteins in hippocampal neurons without
the appearance of aggresome-like structures. However,
proteasome inhibition in rats expressing a higher propor-
tion of i-proteasome (that is, following LPS injection) led
to the formation of neuronal aggresome-like structures.
Importantly, all these biochemical and cellular modifica-
tions were not observed when proteasome inhibition or
Figure 6 LPS+ LT injections increase hippocampal neurodegeneration in young animals. (A) Fluoro-Jade B staining of brain slices of
animals 72 hours after saline + LPS, saline + LT or LPS + LT injection. Images correspond to the CA1, CA3 and dentate gyrus (DG) of the
hippocampal formation. Note the absence of neurodegeneration in saline + LPS rats, agreeing with biochemical data. Saline + LT injection
produced a moderate neurodegeneration, but the number of positive Fluoro-Jade B cells was clearly increased in rats injected with LPS + LT.
Representative photographs with cresyl violet staining are shown in the middle panel: (a) saline + LPS; (b) saline + LT; and (c) LPS + LT. In the lower
panel is shown the immunohistochemistry detection of the neuronal marker NeuN in hippocampal slices from rats injected with (d)saline + LPS;
(e) saline + LT and (f) LPS + LT. Note the strong diminution in the immunolabeling intensity for this neuronal marker in rats injected with LPS + LT.
For orientative purposes, dotted lines represent the localization of the stratum pyramidale and granular layer, where somata of principal neurons
are located. (B) Representative western blot of caspase-3. The amount of processed caspase-3 was higher in the LPS + LT rats in agreement with
biochemical and cellular data. Image corresponding to the processed fragments is overexposed for a better visualization. Experiments were done
in parallel and repeated at least three times with similar results. DG: dentate gyrus; gl: granular layer; LPS: lipopolysaccharide; LT: lactacystin; sp:
stratum pyramidale.
Pintado et al. Journal of Neuroinflammation 2012, 9:87 Page 8 of 10
http://www.jneuroinflammation.com/content/9/1/87neuroinflammation were induced separately. Thus, present
data strongly indicate that neuroinflammation is acting as a
synergic risk factor for intracellular protein accumulation
and neurodegeneration.
Having in mind that acute neuroinflammation
induced by LPS injection in young animals is not at
all similar to neuroinflammatory processes occurring dur-
ing normal aging (chronic neuroinflammation), present
findings could be relevant in the context of hippocampal
aging. In this sense, aged rat hippocampus is characterized
by chronic neuroinflammation [2,4,31]; decreased prote-
asome activity [32,33]; accumulation of ubiquitinated pro-
teins [20,22]; higher proportion of i-proteasome [21]; and
absence of significant neurodegeneration of pyramidal
neurons [2]. Interestingly, LT injection alone in aged
hippocampus reproduced protein accumulation observed
in young rats injected with LPS+LT. Moreover, as we have
previously shown, LT injection in aged rats leads to a pre-
dominant expression of pro-apoptotic proteins Bax, Bak
and caspase-3 in addition to a higher neurodegeneration
compared to young rats subjected to LT injection [22].All of these age-related modifications can be repro-
duced in young animals only when proteasome was
inhibited during the development of a neuroinflamma-
tory response (LPS + LT). Thus, present and previous
data support the idea that chronic neuroinflammation,
as occurs in normal aging and in age-related neurode-
generative diseases (see below), should be considered as
a synergic risk factor for neurodegeneration under situa-
tions of proteasome dysfunction (see [34] for a detailed
review). In consequence, the modulation of neuroinflam-
mation could represent an attractive therapeutic target
in order to delay the onset and/or progression of neuro-
degeneration associated to the age-related neurodegen-
erative diseases [34]. Neuronal i-proteasome expression,
which is almost absent in young healthy human brains,
has been detected in the hippocampus from elderly
patients as well as in patients affected by Alzheimer’s
disease [35]. i-proteasome expression has also been
observed in neurons localized in different brain areas
from patients with Huntington’s disease, multiple scler-
osis and temporal lobe epilepsy, diseases coursing with
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tion whether i-proteasome expression has a protective
role, as a homeostatic attempt of neurons to cope with the
progressive accumulation of damage proteins, or, by con-
trast, has a deleterious effect. In this sense, present and
previous data show evidence for both possibilities: i-
proteasome expression may have a protective role in the
context of acute neuroinflammation, but a detrimental ef-
fect when neuroinflammation become chronic as occurs
in the majority of neurodegenerative diseases.
Conclusions
The mechanisms underlying the neuroprotective role of
i-proteasome in the context of acute neuroinflammation
and its detrimental properties in the context of chronic
neuroinflammation are currently unknown. The com-
prehension of the physiological role of i-proteasome in
neuroinflammation and its participation in neurodegen-
erative diseases coursing with neuroinflammation is an
expanding area in biomedical research. In this sense, the
combination of neuroinflammation and proteasome in-
hibition may be a plausible model for the study of the
physiological role of i-proteasome upon neuroinflamma-
tion and their involvement in diseases with a neuroin-
flammatory component. In summary, we report evidence
supporting the idea that the two main hallmarks of age-
related neurodegenerative diseases may form a neurode-
generative loop.
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